You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
22 October 2024
HepaRegeniX appoints Dr. Martin Bonde as new Chair of the Board
10 July 2024
HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration
14 March 2024
HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell
23 November 2022
HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor
12 May 2022
HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor
30 March 2022
HepaRegeniX appoints Elias Papatheodorou as new Chairman of the Board of Directors
4 November 2021
HepaRegeniX to present key results on MKK4 inhibitors and their therapeutic efficacy at upcoming scientific conferences
20 October 2021
HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination ther
10 August 2021
HepaRegeniX initiates first-in-man Phase 1 trial for its lead MKK4 inhibitor HRX 0215
3 December 2020
HepaRegeniX achieves further milestone related to proof of safety and efficacy for MKK4 inhibition in an advanced chronic liver disease model
19 November 2020
HepaRegeniX hires industry expert Dr. Markus Weissbach as Senior Clinical Advisor
10 November 2020
HepaRegeniX GmbH to deliver an oral presentation of preclinical results on MKK4 inhibition in liver regeneration at The Liver Meeting(R) 2020
20 October 2020
HepaRegeniX GmbH hires industry veteran Dr David Shapiro as Senior Medical Advisor
7 July 2020
HepaRegeniX GmbH achieves successful proof of efficacy in acute liver disease models for selected MKK4 inhibitors
5 January 2017
HepaRegeniX GmbH Raises EUR9 million in a Series A Financing to Develop Kinase Inhibitors for the Treatment of Acute and Chronic Liver Diseases